These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 16828495

  • 1. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [Abstract] [Full Text] [Related]

  • 2. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
    [Abstract] [Full Text] [Related]

  • 3. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
    Pawlak K, Mysliwiec M, Pawlak D.
    Thromb Res; 2008; 122(3):328-35. PubMed ID: 18048089
    [Abstract] [Full Text] [Related]

  • 4. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [Abstract] [Full Text] [Related]

  • 5. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
    Pawlak K, Pawlak D, Myśliwiec M.
    Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
    Zhou H, Wu X, Lu X, Chen G, Ye X, Huang J.
    Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
    [Abstract] [Full Text] [Related]

  • 7. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
    Chu SC, Yang SF, Lue KH, Hsieh YS, Hsiao TY, Lu KH.
    J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
    [Abstract] [Full Text] [Related]

  • 8. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
    Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F.
    Cancer Res; 1998 May 01; 58(9):1843-9. PubMed ID: 9581823
    [Abstract] [Full Text] [Related]

  • 9. Blood urokinase plasminogen activator system in chronic urticaria.
    Kasperska-Zajac A, Brzoza Z, Rogala B.
    Arch Dermatol Res; 2007 Jan 01; 298(8):409-11. PubMed ID: 17102952
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?
    Pawlak K, Ulazka B, Mysliwiec M, Pawlak D.
    Transl Res; 2012 Nov 01; 160(5):346-54. PubMed ID: 22683425
    [Abstract] [Full Text] [Related]

  • 11. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
    Yeh YH, Wang PH, Lin LY, Tee YT, Chou MC, Yang SF, Tsai HT.
    Clin Chim Acta; 2013 Jan 16; 415():138-44. PubMed ID: 23117033
    [Abstract] [Full Text] [Related]

  • 12. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality.
    Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, Eugen-Olsen J.
    Clin Microbiol Infect; 2004 May 16; 10(5):409-15. PubMed ID: 15113317
    [Abstract] [Full Text] [Related]

  • 13. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R, Stephens RW, Brünner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhoff GF.
    Gynecol Oncol; 2001 Sep 16; 82(3):523-31. PubMed ID: 11520150
    [Abstract] [Full Text] [Related]

  • 14. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.
    Pawlak K, Mysliwiec M, Pawlak D.
    Thromb Res; 2010 Feb 16; 125(2):e40-5. PubMed ID: 19732942
    [Abstract] [Full Text] [Related]

  • 15. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Thromb Res; 2007 Feb 16; 120(6):871-6. PubMed ID: 17331567
    [Abstract] [Full Text] [Related]

  • 16. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR, Wang Q, Shi SS, Lu MH, Guo WD.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb 16; 12(2):82-4. PubMed ID: 14980106
    [Abstract] [Full Text] [Related]

  • 17. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
    Pawlak K, Buraczewska-Buczko A, Mysliwiec M, Pawlak D.
    Am J Med Sci; 2010 Jan 16; 339(1):5-9. PubMed ID: 19926968
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Høyer-Hansen G, Smith K, Brünner N, Harris AL.
    Clin Cancer Res; 2002 May 16; 8(5):1132-41. PubMed ID: 12006529
    [Abstract] [Full Text] [Related]

  • 19. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR, Piironen T, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H.
    Scand J Immunol; 2005 Apr 16; 61(4):347-56. PubMed ID: 15853918
    [Abstract] [Full Text] [Related]

  • 20. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD, Høgdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, Glud E, Høyer-Hansen G, Ring-Larsen H, Høgdall EV.
    Anticancer Res; 2004 Apr 16; 24(3b):1981-5. PubMed ID: 15274388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.